Discovery of Novel Decarboxylase Inhibitors via an In Silico – In Vitro Approach for Enhancing l -DOPA Therapy in Parkinson’s Disease

Abstract Parkinson’s disease (PD) is the second most common neurodegenerative disease, with increasing global prevalence. Its hallmark motor symptoms are managed most effectively with levodopa (l-DOPA), which remains the mainstay of symptomatic therapy. The oral bioavailability of l-DOPA is low and variable for several reasons, among which presystemic decarboxylation by human DOPA decarboxylase (DDC) and by gut bacterial tyrosine decarboxylase (TyrDC) is a major pharmacologically addressable contributor. Current DDC inhibitors (e.g., carbidopa) fail to block bacterial TyrDC, allowing l-DOPA to be lost in the gut. Here, we report the discovery of inhibitors targeting both human and bacterial decarboxylases using a combined in silico–in vitro workflow. Virtual screening of 1.6 million compounds against Enterococcus faecalis TyrDC yielded 505 candidates; primary biochemical screening identified 22 hits (>20% inhibition at 100 μM). Hit expansion via similarity search and synthesis of a 23-analog library produced compounds with improved potency belonging to four diverse scaffolds. Selected compounds inhibited recombinant E. faecalis TyrDC with micromolar potency (IC50 10–360 μM) and reduced l-DOPA conversion in E. faecalis whole-cell assays (up to 70% inhibition at 100 μM). Some of the compounds also displayed moderate potency toward human DDC (IC50 59–871 μM) and low cytotoxicity toward HeLa cells (CC50 > 100 μM for most). A moderate correlation (r = 0.59) between TyrDC and DDC inhibition suggests partially shared binding features, and molecular docking of the most potent dual inhibitor into the crystal structures of both enzymes provided additional insights into binding mode similarities and differences between the two enzymes. Notably, several compounds reduced l-DOPA conversion in whole-cell assays without measurably inhibiting recombinant TyrDC, indicating that whole-cell activity in this system is not fully explained by direct enzyme inhibition. These four scaffolds provide starting points for the development of TyrDC- and/or DDC-directed inhibitors.

Authors

Institutions

Publication Details

Journal
ACS Omega
Published
2026-11-13
DOI
https://doi.org/10.1021/acsomega.6c06924
Primary Topic
Computational Drug Discovery Methods
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Discovery of Novel Decarboxylase Inhibitors via an In Silico – In Vitro Approach for Enhancing l -DOPA Therapy in Parkinson’s Disease

Henri Xhaard, Michael Jeltsch, Päivi Tammela, Jayendra Z. Patel et al.
1 links
ACS Omega
Computational Drug Discovery Methods
article

Discovery of Novel Decarboxylase Inhibitors via an In Silico – In Vitro Approach for Enhancing l -DOPA Therapy in Parkinson’s Disease

Henri Xhaard, Michael Jeltsch, Päivi Tammela, Jayendra Z. Patel, Léo Ghemtio, Jari T. Yli‐Kauhaluoma, Saku Reunanen, Häkkinen Henrik, Petteri Piepponen
article en

Abstract

Abstract Parkinson’s disease (PD) is the second most common neurodegenerative disease, with increasing global prevalence. Its hallmark motor symptoms are managed most effectively with levodopa (l-DOPA), which remains the mainstay of symptomatic therapy. The oral bioavailability of l-DOPA is low and variable for several reasons, among which presystemic decarboxylation by human DOPA decarboxylase (DDC) and by gut bacterial tyrosine decarboxylase (TyrDC) is a major pharmacologically addressable contributor. Current DDC inhibitors (e.g., carbidopa) fail to block bacterial TyrDC, allowing l-DOPA to be lost in the gut. Here, we report the discovery of inhibitors targeting both human and bacterial decarboxylases using a combined in silico–in vitro workflow. Virtual screening of 1.6 million compounds against Enterococcus faecalis TyrDC yielded 505 candidates; primary biochemical screening identified 22 hits (>20% inhibition at 100 μM). Hit expansion via similarity search and synthesis of a 23-analog library produced compounds with improved potency belonging to four diverse scaffolds. Selected compounds inhibited recombinant E. faecalis TyrDC with micromolar potency (IC50 10–360 μM) and reduced l-DOPA conversion in E. faecalis whole-cell assays (up to 70% inhibition at 100 μM). Some of the compounds also displayed moderate potency toward human DDC (IC50 59–871 μM) and low cytotoxicity toward HeLa cells (CC50 > 100 μM for most). A moderate correlation (r = 0.59) between TyrDC and DDC inhibition suggests partially shared binding features, and molecular docking of the most potent dual inhibitor into the crystal structures of both enzymes provided additional insights into binding mode similarities and differences between the two enzymes. Notably, several compounds reduced l-DOPA conversion in whole-cell assays without measurably inhibiting recombinant TyrDC, indicating that whole-cell activity in this system is not fully explained by direct enzyme inhibition. These four scaffolds provide starting points for the development of TyrDC- and/or DDC-directed inhibitors.

ACS Omega
University of Helsinki (FI)
Harvard University, Helsingin Yliopisto, Biocodex Microbiota Foundation, Päivikki ja Sakari Sohlbergin Säätiö, Biocenter Finland, Parkinsonfonden, Helsinki Institute of Life Science, Helsingin Yliopisto, Suomen Parkinson-säätiö
Good health and well-being
Computational Drug Discovery Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon